



The role of the innate immune system in granulomatous disorders

Helen J. Petersen¹ and Andrew M. Smith²*

¹ Eastman Dental Institute, University College London, London, UK

² Department of Medicine, University College London, London, UK

Edited by:

Claudia Monaco, Catholic University Rome, Italy; Imperial College, UK

Reviewed by:

Jean-Christophe Renauld, Ludwig Institute for Cancer Research, Belgium

Masato Kubo, Tokyo University of Science, Japan

*Correspondence:

Andrew M. Smith, Department of Medicine, Rayne Institute, 5 University Street, London WC1E 6BT, UK.

e-mail: andrew.m.smith@ucl.ac.uk

The dynamic structure of the granuloma serves to protect the body from microbiological challenge. This organized aggregate of immune cells seeks to contain this challenge and protect against dissemination, giving host immune cells a chance to eradicate the threat. A number of systemic diseases are characterized by this specialized inflammatory process and granulomas have been shown to develop at multiple body sites and in various tissues. Central to this process is the macrophage and the arms of the innate immune response. This review seeks to explore how the innate immune response drives this inflammatory process in a contrast of diseases, particularly those with a component of immunodeficiency. By understanding the genes and inflammatory mechanisms behind this specialized immune response, will guide research in the development of novel therapeutics to combat granulomatous diseases.

Keywords: granuloma, Crohn's, innate, macrophage, neutrophil, autophagy

INTRODUCTION

The innate immune system plays a central role in driving inflammation and protecting the body from invading microorganisms. This first line of defense is made up of white blood cells, secretory molecules, and proteins which form an anatomical barrier to infection. Components of the innate immune system are important for orchestrating granuloma formation in response to microbial and foreign body challenge. This specialized inflammatory process can occur throughout the body, varying in size, organization, and composition of innate immune cells involved. The ultimate function of the granuloma is to contain and eradicate microorganisms or chronic irritants that are resistant to elimination through the normal immune response. This process is finely balanced between host protection and localized collateral damage to normal tissue and potential loss of function.

An emerging concept that this specialized inflammatory process is in fact a last resort when other immune protective processes have failed is slowly becoming recognized. A number of immunodeficiency disorders hereditary and acquired, present with granulomatous inflammation at a variety of body sites. Granuloma formation in patients with these disorders often has an infective prequel. Failure to clear the infective organism results in persistence and subsequent granuloma formation to try to contain the infection. The aim of this review is to explore the role of the innate immune system and its aberrant disorders in the formation of the granuloma.

GRANULOMA FORMATION AND ROLE IN IMMUNODEFENSE

A granuloma is a collection of inflammatory cells, predominantly mature macrophages that form an aggregate in response to an antigen. This antigen can include invading bacteria, fungi, foreign bodies, and immune complexes (James, 2000; Schappi et al., 2008; Ramakrishnan, 2012). The purpose of the granuloma is to

isolate this antigen from the body and to facilitate its eradication. This crucial immune reaction serves to protect the body from dissemination of the antigen, this being especially important in the case of mycobacterial infections. Immune defects, in particular ones that specifically affect the innate immune system have been shown to result in poor granuloma formation. Deficiency in tumor necrosis factor alpha (TNF α), Interleukin 12 (IL-12), or interferon gamma (IFN γ) also result in poor granuloma formation (Ramakrishnan, 2012).

On initiation of the granulomatous response, antigen presenting cells encountering an antigen release a cocktail of pro-inflammatory cytokines and chemoattractants. This recruits neutrophils from the circulation into the infected area and these in turn release additional cytokines to attract and activate monocytes. Under normal circumstances the recruited neutrophils eliminate the infective agent through the process of phagocytosis and digestion within the phagocytic vacuole (Segal, 2005). When the infective agent is resistant to neutrophil clearance macrophages engulf the antigen. Upon internalization, macrophages secrete additional pro-inflammatory mediators and attempt to digest the foreign body in order to present antigen derived peptides and lipids via MHC class II and CD1 molecules to T cells, natural killer T cells (NKT cells), and natural killer cells (NK cells). IFN γ secreted by NK cells, NKT cells, and T cells, activates dendritic cells. The dendritic cells in turn release copious amounts of TNF α to further promote the influx of immune cells to the area, creating a specialized microenvironment to deal with the foreign antigen (Figure 1A). Upon internalization of the antigen, macrophages secrete additional pro-inflammatory mediators and attempt to digest the foreign body in order to present antigen derived peptides and lipids via MHC class II and CD1 molecules to T antigen. The dendritic cells also migrate to the local lymph nodes to present the antigen to naïve CD4 cells. On secretion of IL-12 by dendritic cells,

these naïve cells differentiate into T-helper 1 (Th1) cells, which secrete IL-2 to promote their survival and expand their population. Activated Th1 cells enter the circulation and are attracted into the granuloma through the high levels of chemokines and adhesion molecules present on the macrovascular endothelial cells. They move about the granuloma using the macrophages as a scaffold to crawl over (Egen et al., 2008), the granuloma resembles a fluid bag rather than a “walled off” solid structure with cells freely moving within in it (Savill and Fadok, 2000; Taylor et al., 2008).

Persistence of the antigen past this point leads to further chronicity of the inflammation and a mature granuloma. Complex cross talk between the individual immune cells and the surrounding epithelium via the production of high levels of TNF α and IFN γ leads to further maturation of macrophages. These macrophages become multinucleate giant cells, with increased phagocytosis and bacterial digestion capabilities. This is all aimed at trying to eradicate the antigen. After a number of weeks, these cells become terminally differentiated into epithelioid macrophages which contain large number of lysosomes, mitochondria, and are engaged in continued endocytic activity. Well-developed pseudopodia, allows for close interdigitation and a tightly packed aggregation of these enlarged cells. Finally, fibrosis occurs.

RELATION TO HUMAN DISEASE

A plethora of diseases in humans feature granulomatous inflammation including infective, neoplastic, vasculitic immunodeficiency states, and inflammopathies (Table 1). The rate of turnover of macrophages is key to the histological presentation of the granuloma. A highly toxic stimulus will result in macrophage death, such as seen in epithelioid granulomas. Examples of this are granulomas seen in tuberculosis and cat’s scratch disease. This results in constant influx of new macrophages to replace the dead cells. Whereas, an inert stimulus will result in a granuloma with low turnover of macrophages.

INFECTIVE GRANULOMAS

As the most frequent cause of granulomas, *Mycobacterium tuberculosis* has killed more people throughout history than any other infective disease (Lawn and Zumla, 2011). This suggests that tuberculous granulomas are not always efficient at eradicating this pathogen. Tuberculosis infections often manifest themselves in immunodeficiency states, suggesting that the innate immune system is key to maintaining effective granuloma formation and eradication of *M. tuberculosis*. Recent research shows that this intracellular pathogen can exploit the innate immune system in the early stages of granuloma formation to facilitate its persistence and potential systemic dissemination. On inhalation *M. tuberculosis* is rapidly phagocytosed by resident lung macrophages. They quickly replicate inside the macrophages and are transported to the surrounding tissues inside these cells. To try and prevent further dissemination and to ultimately exterminate the microorganism, granuloma formation is initiated.

The importance of the innate immune system in tuberculous granuloma formation is highlighted by the zebrafish model. Zebrafish larvae do not have an adaptive immune system, yet still form highly organized granulomas. Imaging studies inside zebrafish have shown macrophages arriving at a forming

Table 1 | Table of granulomatous disorders.

Granulomatous disease
I. INFECTIONS
<ul style="list-style-type: none"> • Fungi <ul style="list-style-type: none"> ◦ <i>Histoplasma</i> ◦ <i>Coccidioides</i> ◦ <i>Blastomyces</i> ◦ <i>Sporothrix</i> ◦ <i>Aspergillus</i> ◦ <i>Cryptococcus</i> • Protozoa <ul style="list-style-type: none"> ◦ <i>Toxoplasma</i> ◦ <i>Leishmania</i> • Metazoa <ul style="list-style-type: none"> ◦ <i>Schistosoma</i> • Spirochetes <ul style="list-style-type: none"> ◦ <i>T. palladium</i> ◦ <i>T. carateum</i> ◦ <i>T. perunue</i> • Mycobacteria <ul style="list-style-type: none"> ◦ <i>M. tuberculosis</i> ◦ <i>M. kansasii</i> ◦ <i>M. leprae</i> ◦ <i>M. marinum</i> ◦ <i>M. avian</i> ◦ BCG vaccine • Bacteria <ul style="list-style-type: none"> ◦ <i>Brucella</i> ◦ <i>Yersinia</i>
2. VASCULITIS
<ul style="list-style-type: none"> • Wegener’s granulomatosis • Necrotizing sarcoidal • Churg–Strauss • Broncho centric • Polyarteritis nodosa • Lymphomatoid • Giant cell arteritis • Systemic lupus erythematosus • Beçhets disease
3. IMMUNOLOGICAL ABERRATIONS
<ul style="list-style-type: none"> • Crohn’s disease • Orofacial granulomatosis • Sarcoidosis • Langerhan’s granulomatosis • Hepatic granulomatous disease • Primary biliary cirrhosis • Blau’s syndrome • Peyronie’s disease • Immune complex disease • Histiocytosis X
4. CHEMICALS
<ul style="list-style-type: none"> • Beryllium • Zirconium • Silica

(Continued)

Table 1 | Continued

Granulomatous disease

- Starch
- Talc

5. NEOPLASIA

- Carcinoma
- Reticulosis
- Pinealoma
- Dysgerminoma
- Seminoma
- Reticulum cell sarcoma
- Malignant nasal granuloma

6. MISCELLANEOUS INFECTIONS

- Whipple's disease
- Cat scratch
- Lymphogranuloma
- Kikuchi
- Buruli ulcer

8. HYPERSENSITIVITY PNEUMONITIS

- Farmers' lung
- Bird fanciers'
- Suberosis (cork dust)
- Mushroom workers'
- Maple bark strippers'
- Bagassosis
- Paprika splitters'
- Spatlese lung
- Coffee bean

10. IMMUNODEFICIENCIES

- Chediak–Higashi
- Ataxia telangiectasia
- NBS
- RAG deficiency
- Artemis deficiency
- Jak3 deficiency
- HLA class I deficiency (TAP deficiency)
- Griscelli syndrome
- Common variable immunodeficiency
- Kabuki syndrome
- HIV (bacillary angiomatosis)
- CGD
- Hermansky–Pudlak
- Felty's syndrome
- Common variable ID (CVID)
- Cartilage-hair hypoplasia SCID

granuloma moving fluidly and rapidly within it (Davis et al., 2002). On encountering a dying macrophage, the incoming macrophage phagocytoses the dying cell and is subsequently infected with *M. tuberculosis*. The chemotaxis of macrophages into the granuloma is orchestrated by the *M. tuberculosis* RD-1 virulence locus, which encodes a type VII secretion system ESX-1 and its substrate ESAT-6. Strains lacking RD-1 have reduced macrophage ingress into what is a poorly formed granuloma and an attenuated infection. This is suggestive that *M. tuberculosis* utilizes

granuloma formation as a protective mechanism to ensure its survival. TNF α was thought to play a central role in tuberculous granuloma formation as TNF α deficient mice showed poor granuloma formation. Studies in zebrafish have now shown this may not be the case as granulomas still form in the absence of TNF α , but are not maintained. Due to a lack of TNF α , macrophages are unable to effectively kill and digest the ingested Mycobacteria. The structure of the granuloma is lost in TNF α deficient animals when these overburdened macrophages die (Clay et al., 2008). The importance of TNF α in granuloma integrity is clearly illustrated in the reactivation of latent *M. tuberculosis* in humans undergoing anti-TNF α antibody therapy. Reactivation of infection is results from an impairment in bacterial containment due to the loss of a fully functional granuloma and reduced CD8⁺ T cell immunity during therapy (Miller and Ernst, 2009). Neutrophils also play a central role in the tuberculous granuloma with peak levels at 3 weeks after inoculation (Wolf et al., 2007). Failure of normal macrophage functioning in granuloma results in an increase of these cells in the granuloma. The consequence of impaired macrophage microbicidal activity is the onset of necrosis which attracts neutrophils into the granuloma in response (Cooper et al., 1993; MacMicking et al., 2003). Increased neutrophil ingress has been shown to herald increased pathology in *M. tuberculosis* infections. Deficiency in caspase recruitment domain-containing protein 9 (CARD9) results in neutrophil-rich granulomas (Dorhoi et al., 2010; Redford et al., 2010). CARD9 mediates signals from so called pattern-recognition receptors such as toll-like receptors (TLRs), NOD-like receptors (NLRs), and dectin-1 activate downstream pathways, including NF- κ B. This subsequently induces the release of cytokines to stimulate/regulate the innate and adaptive immune responses. One such cytokine is the immunomodulator IL-10, essential for downregulation of IL-23 signaling and subsequent IL17 production. IL-17 is secreted by Th-17 and $\gamma\delta$ T cells and leads to mass neutrophil influx into the granuloma (Lockhart et al., 2006). This is supported by the fact peak neutrophil influx occurs around day 21 and coincides with the activation of the adaptive immune response. In schistosome infection however, a Th-2 dominant response is mounted, absence of the Th-2 cytokine IL-4 results in increased hepatocyte damage, driven by excessive proinflammatory mediator secretion. This suggests the Th-2 response is protective for excessive immune stimulation and response to schistosome eggs (Pearce et al., 2004). Dorhoi et al. showed that CARD9 knockout mice failed to secrete IL-10 and produced neutrophilic granulomas due to increased IL-17 levels. These mice subsequently died from an aberrant excessive inflammatory response that resulted in the dissemination of the infection (Dorhoi et al., 2010). A role for CARD9 in the development of Crohn's disease has also been highlighted through its identification in genome wide association studies (GWAS) (Franke et al., 2010).

COMPLEX DISEASE OF ABERRANT IMMUNE FUNCTION**Sarcoidosis**

Sarcoidosis is a systemic disease affecting multiple systems, but particularly barrier tissues such as the lungs, eyes, and skin (Rastogi et al., 2011). Current research has suggested that both environmental and genetic factors play a role in this complex disease. A GWAS

conducted using 499 German individuals with sarcoidosis and 490 controls, detected an association to the ANXA11 (annexin 11) gene on chromosome 10q22.3 (Hofmann et al., 2008). This protein has been implicated in a number of functions including vesicle trafficking and apoptosis (Gerke and Moss, 2002). It is thought that the prevention of propagation of granulomatous inflammation is controlled by apoptotic mechanisms of inflammatory cells. It facilitates calcium dependent interaction with ALG-2 a glycosyltransferase, which is necessary for caspase cell-induced death (Rao et al., 2004). It is therefore possible if annexin 11 regulated apoptotic mechanisms are affected because of this mutation, activated inflammatory cells survive and drive the granulomatous response further to cause wide spread disease.

High levels of TNF α and IL-12 in the serum of patients with the disease has been shown and also increased production of these cytokines by peripheral blood monocytes and alveolar macrophages (Prior et al., 1996). Macrophages are important defense cells in the lungs and are critical for initiating an inflammatory response on stimulation by inhaled microbes and toxins. This is facilitated through recognition of pathogen-associated molecular patterns (PAMPs) through pattern-recognition receptors such as TLRs and NLRs. Rastogi et al. (2011) have shown that the high cytokine levels detected in patients with sarcoidosis is down to stimulation of alveolar macrophages with TLR4 and NOD1 agonists. This in turn leads to sustained p38 phosphorylation and cytokine production, particularly increased transcription of IL-12, TNF α , and IL-1 (Dong et al., 2002; Inoue et al., 2006). TNF α maintains the integrity and maintenance of the granuloma and limits the influx of inflammatory cells to the granuloma to prevent escalation of the inflammatory process.

Paradoxically, anti-TNF α induced sarcoidosis has also been reported in the literature, mainly affecting the lungs, parotid, and skin (Massara et al., 2010). After withdrawal of anti-TNF α therapy the condition resolves, it is thought that the cytokine imbalance experienced on prolonged TNF α blockade precludes the disease. Corticosteroid therapy has also been shown to be detrimental in recent onset disease (Reich, 2003, 2012).

Dendritic cells play a central role in granuloma formation by directly recruiting immune cells via TNF α secretion and indirectly through the activation of T cells via presentation of antigen in the surrounding lymph nodes. Patients with sarcoidosis have shown to present with a deficit in delayed type hypersensitivity reactions through impairment of dendritic cell functioning (Mathew et al., 2008). The same group also showed that sarcoid patients have comparable levels of circulating dendritic cells to that of healthy controls, but these dendritic cells display anergy to microbial challenge, despite the presence of upregulated costimulatory and maturation markers (Mathew et al., 2008). This dysfunction is mild and therefore does not predispose these individuals to severe microbial infections as seen with those with primary immunodeficiencies. The same group also demonstrated a correlation between the degree of dendritic cell dysfunction and severity of pulmonary disease.

It has also been suggested that Tuberculosis and sarcoidosis are different spectrums of the same disease (Gupta et al., 2012). The histological and clinical similarities of both diseases could point to the fact that sarcoidosis is immune hypersensitivity to

mycobacterial antigens, whilst in patients with tuberculosis; an underactive immune process.

Primary biliary cirrhosis

Activation of the innate immune system in this organ specific autoimmune disorder is thought to be key in the early stages of this disease as seen by eosinophilic infiltrations and elevated IgM (Berg, 2011). Biliary epithelial cells express a number of pattern-recognition receptors and are the first line of defense against foreign invaders in the liver. They are repeatedly exposed to PAMPs and through TLR and NLR signaling eventually undergo apoptosis. It is hypothesized that increased activation of apoptosis within these cells is via loss or down regulation of Bcl-2 and this in turn plays a major role in the disease process (Garchon et al., 1994). Poor clearance of these apoptotic and damaged cells by macrophages leads to their persistence and subsequent stimulation of the adaptive immune response and the tissue damage and granuloma formation that ensues, which is thought to be the primary mechanism driving the disease process. Particularly, exposure of mitochondrial membrane proteins leads to production of anti-mitochondrial autoantibodies (AMAs) which are a feature of the disease. This can lead to development of concomitant autoimmune disorders (Watt et al., 2004). The balance between bile duct proliferation and damage is the hallmark of this disease process which affects biliary epithelial cells.

GRANULOMA FORMATION IN IMMUNODEFICIENCY STATES

A number of immunodeficiency disorders present with granulomatous inflammation, including hereditary immunodeficiency states such as common variable immunodeficiency and chronic granulomatous disease (CGD). Diseases which present with granulomas such as Crohn's disease have also recently been shown to have an element of immunodeficiency (Rahman et al., 2008).

Crohn's disease

One of the most common causes of granuloma formation in the gastrointestinal tract is the inflammatory bowel disorder; Crohn's disease. Granulomas in Crohn's patients can occur anywhere along the gastrointestinal tract from the mouth to the rectum. A complex interplay between the microbial contents, estimated to be 10^{14} bacteria, the epithelium and immune components drives this disease process. The gastrointestinal tract has a multi-layered defense system which consists of physical barriers, anti-bacterial molecules, and a range of leukocytes. Epithelial goblet cells secrete mucins, which act as a barrier to invading bacteria, whilst paneth cells secrete defensins which are primitive microbicidal peptides. Innate immune cells such as macrophages and dendritic cells are present in the lamina propria for immunosurveillance. It is thought that a breakdown in this complex homeostasis between the gut microflora and host defense mechanisms is the precipitating cause to Crohn's (Marks and Segal, 2008). A major hypothesis centers on the impaired handling and clearance of luminal content which gains access into the bowel wall (Sewell et al., 2009). The precise mechanisms responsible for this impaired innate immune response are still not fully understood. Recent GWAS (Barrett et al., 2008; Franke et al., 2010) have identified over 70 genetic polymorphisms associated with Crohn's and this number is expected to

increase over the next few years (Lees et al., 2011). Many of these loci have been linked to genes involved in bacterial recognition, innate immunity, and autophagy. Interestingly a large proportion of the genes identified are also associated with other immune conditions illustrating common pathological processes in quite different phenotypes (Lees et al., 2011).

Genome wide association studies have identified several genes associated with autophagy (*ATG16L1*, *IRGM*, *LRRK2*, *ULK1*, and *NOD2*) (Levine and Deretic, 2007). *NOD2* the most strongly associated gene with Crohn's disease is responsible for pro-inflammatory cytokine release and autophagy induction (Hugot et al., 2001; Ogura et al., 2001; Travassos et al., 2010). Expressed predominantly by macrophages, *NOD2* recruits another Crohn's associated protein *ATG16L1* to the cell membrane and acts as a sensor for bacterial peptidoglycan smallest subunit *N*-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) and activating autophagy machinery (Torok et al., 2009). Numerous genetic studies have identified three *NOD2* polymorphisms rs2066844 (R702W), rs2066845 (G908R), and rs2066847 (1007fs) as being associated with increased susceptibility for Crohn's disease, common to all three is a loss in MDP sensitivity and an inability to activate downstream targets, thus inducing an immunodeficiency in carriers (Burton et al., 2007; Franke et al., 2010). *ATG16L1* is expressed in the epithelial cells of the intestine, in leukocytes, and the spleen (Fujita et al., 2008). Studies have shown that mutation of *ATG16L1* (T300A) has an association with the formation of ileal Crohn's disease (Prescott et al., 2007; Sventoraityte et al., 2010).

The mechanism of autophagy within the gut and has a number of functions to maintain homeostasis. The first of these is intracellular defense against microorganisms via the process of xenophagy (Gardet and Xavier, 2012). This is thought to be important in the tight control of the innate immune response against commensal gut organisms. If this process is affected and bacterial handling impaired, this can lead to an inappropriate host inflammatory response against commensal organisms. Some of these genes (*IRGM*, *NOD2*, *LRRK2*) are also associated with infective granulomatous disorders, thus suggesting Crohn's patients may have altered control of mycobacterial infections (Intemann et al., 2009; Kumar et al., 2010). Autophagy proteins have also been shown to be involved in the regulation of the inflammasome through defects in mitochondrial autophagy leading to increase reactive oxygen species and loss of regulation of inflammasome pathways, particularly the pro-IL-1 β pathway. Plantinga et al. (2011) demonstrated that mutation in *ATG16L1* results in monocytes with increased IL1 β secretion on stimulation with MDP. Dendritic cells also rely on autophagy for antigen presentation (Schmid et al., 2007). Recent evidence has suggested that defects in autophagy proteins may destabilize the immune cross talk between dendritic cells and T cells leading to an increased inflammatory response (Wildenberg et al., 2012). It can be assumed that this could add to the collateral damage caused by the immune system within the gut. The last function of autophagy is maintenance of secretory granules in paneth cells, which have a role in innate immune defense in the gut. *NOD2* and *ATG16L1* are expressed by paneth cells, and through NLR and TLR signaling pathways these cells release a cocktail of antimicrobial proteins, including lysozyme,

but principally they secrete alpha defensins. These hydrophobic peptides are pore forming units that disrupt bacterial cell membrane leading to lysis and death. The 1007fs mutation in *NOD2* has been proven to decrease defensin expression and this is supported by the observation that patients with *NOD2* mutations have lower defensins titers in ileostomy fluid compared to controls (Wehkamp et al., 2005; Van Limbergen et al., 2007). Lower levels of these proteins could facilitate entry of bacteria into the epithelial cells and a breach in the mucosal integrity. The T300A mutation in *ATG16L1* also results in a decrease in secretory granule number within paneth cells. This loss of the mucosal barrier is the first step in the suggested multistep pathogenesis of Crohn's (Marks and Segal, 2008). The next step involves reduction in bacterial killing capacity and clearance by neutrophils (Figure 1B).

Neutrophils play a central role in bacterial clearance from the gut and in the etiopathogenesis of Crohn's. The importance of neutrophils in gut immunity becomes clear when you consider monogenic diseases that result in neutrophil dysfunction and the high incidence in bowel inflammation in these patients. These diseases are covered in more detail in the following section and a recent review (Rahman et al., 2008). A profound defect in the recruitment of neutrophils into tissues after stimulation with heat killed *Escherichia coli* and the subsequent failure to adequately clear this bacterial challenge has been identified in patients with Crohn's disease (Smith et al., 2009). The neutrophils themselves function normally, but impaired cytokine secretion from macrophages results in their failure to accumulate in adequate numbers in the tissues (Marks et al., 2006; Smith et al., 2009). The consequence of this delayed recruitment results in bacteria remaining in the tissue, macrophages engulf the remaining bacteria and fecal matter inciting an inflammatory response culminating in granuloma formation. The defect is within the macrophage, specifically the vesicular trafficking and secretion of cytokines. Gene transcription and synthesis of TNF α was found to be normal in macrophages of Crohn's disease patients, but secreted levels were grossly attenuated as a result of defective intracellular trafficking (Smith et al., 2009).

IL23R is another gene with several SNPs associated with Crohn's disease (Duerr et al., 2006) as well as members of the IL23 pathway; Jak2 and STAT3 (Barrett et al., 2008). Secreted by activated dendritic cells, macrophages and monocytes, IL23 induces the development of TH17 cells and induces IL1, IL6, and TNF α from macrophages and monocytes. Primary immunodeficiencies characterized by mutations in IL23 pathway genes also present with granulomatous inflammation (see Table 2).

All these disorders have defects with the innate immune response and form granulomas in various tissues throughout the body.

The association of genes in autophagy regulation, IL-23 pathway, and defects in bacterial handling lends itself to the formation of the hypothesis that Crohn's results from a defect in the digestion and removal of bacteria from the tissue. The remaining bacteria are walled off in the tissue and a granuloma forms to restrict dissemination of any infective agents. The granuloma then secretes pro-inflammatory cytokines and presents antigens to the adaptive immune system resulting in T cell activation. This response drives a chronic inflammatory condition which is the hallmark of

Table 2 | Immunodeficiency disorders that present with granulomatous inflammation.

Disease	Gene	Inheritance	Granuloma location	Reference
Hermansky–Pudlak syndrome	<i>HPS-1, HPS-3, 10q23.1-23.3</i>	Autosomal recessive	GI tract	Schinella et al. (1980)
Chronic granulomatous disease	<i>NCF1, NCF2, CYBA, and CYBB</i>	X-linked or autosomal recessive	Liver, mouth, skin, lungs, urinary tract, GI tract	Segal et al. (1978)
Chediak–Higashi disease	<i>CHS1 (LYST), 1q42-43</i>	Autosomal recessive	GI tract	Ishii et al. (1987)
RAG deficiency	<i>RAG1 RAG2</i> genes	Autosomal recessive	Cutaneous, mucous membranes, and internal organs	Schuetz et al. (2008)
Artemis deficiency (SCID-Athabascan)	<i>DCLRE1C</i>	Autosomal recessive	Cutaneous	IJspeert et al. (2011)
Janus kinase 3 (Jak3) deficiency	<i>ILR2G</i>	Autosomal recessive form of severe combined immunodeficiency (SCID)	Cutaneous	Gregoriou et al. (2008)
Griscelli syndrome	<i>RAB27a</i>	Autosomal recessive	Cutaneous	Eyer et al. (1998)
Common variable immunodeficiency (CVID)	<i>ICOS, TNFRSF13B</i> (encoding TACI), <i>TNFRSF13C</i> (encoding BAFF-R), and <i>CD19</i> .	Autosomal recessive and dominant forms	Lung, liver, skin, heart, eyes, gastrointestinal tract, and splenic granulomas	Ardeniz and Cunningham-Rundles (2009)
Ataxia telangiectasia	<i>A-T</i> mutated gene (11q22-23)	Autosomal recessive	Cutaneous granulomas	Chiam et al. (2011)
Nijmegen breakage syndrome (NBS)	<i>nbs1(8q21)</i>	Autosomal recessive	Cutaneous	Yoo et al. (2008)
TAP deficiency/bare lymphocyte syndrome type 1 group 3 (BLS)	<i>tap1 tap 2</i> genes	Autosomal recessive	Necrotizing cutaneous, gut and lung granulomas	Moins-Teisserenc et al. (1999), Zimmer et al. (2005)
Wiskott–Aldrich syndrome	WAS gene, on the X-chromosome (Xp11.23-p11.22)	X-linked recessive	Cutaneous	Sebire et al. (2003)
Hyper IgM	CD40L gene long arm of the X-chromosome (Xq26-27.2)	X-linked recessive (autosomal recessive and dominant forms)	Cutaneous	Gallerani et al. (2004)

Crohn's disease and the focus of the majority of current therapeutic agents. Future drug design could target the defective bacterial clearance by boosting macrophage function and subsequently reducing granuloma formation which may prove advantageous.

Monogenic disorders of neutrophil function

Although neutrophil defects do not appear to be the primary cause of Crohn's, disorders which result in low neutrophil numbers such as cyclical neutropenia, disorders of bacterial digestion such as CGD and disorders of impaired vesicle trafficking and expulsion (Chediak–Higashi and Hermansky–Pudlak syndromes), can present with a Crohn's-like gut. This includes granuloma formation in the lamina propria and ulceration. Approximately half of all CGD patients develop bowel inflammation which is indistinguishable from Crohn's disease (Marks et al., 2009). These observations support the important role of neutrophils in healthy gut maintenance and a reduction of functioning in granuloma formation.

Chronic granulomatous disease affects primarily males and is a rare congenital disease that is either X-linked or autosomal recessive (Holland, 2010). This disorder is characterized by a defect in the superoxide generating NADPH oxidase system in neutrophils which is necessary for killing microorganisms by respiratory burst. The pathognomic feature of CGD is recurrent infections, particularly by catalase positive bacteria and fungi (Martire et al., 2008). This impaired bacterial killing leads to granuloma formation in a variety of organs including the liver, gut, skin, and mouth (Levine et al., 2005). Defects of the proteins which are responsible for governing the respiratory burst to generate reactive oxygen species have been identified as the cause of this condition (Dinauer et al., 1987; Volpp et al., 1988; Clark et al., 1989). An unbalance in the expression of innate immune receptors on neutrophils has also been shown to have a causal role in CGD. Neutrophils in CGD patients show reduced expression of TLR5, TLR9, and CD18, reduced TLR5 levels resulting in reduced activation by bacterial flagella. Lowered CD18

expression results in impaired killing of *Staphylococcus aureus*. Both TLR5 and TLR9 expression levels have been shown to correlate with the severity of the disease, higher expression seen in patients with higher residual NADPH oxidase and a less severe phenotype (Rieber et al., 2012). Many CGD patients suffer from concomitant autoinflammatory conditions such as systemic lupus erythematosus and pulmonary fibrosis, potentially suggesting an

uncontrolled inflammatory response tipping toward hyperinflammation (Winkelstein et al., 2000; Rieber et al., 2012). Upregulation of several pro-inflammatory genes has been identified by microarray analysis on activation of TLR2 or TLR4, which is independent of NADPH oxidase activity (Kobayashi et al., 2004; Bylund et al., 2007). In addition to the neutrophil the NADPH oxidase system is utilized by the macrophage and defective immune responses




FIGURE 1 | Continued




FIGURE 1 | (A) Diagram of a mature granuloma. After 3 weeks of maturation, the granuloma is fully formed. Crosstalk between various cells of the immune system leads to proliferation of lymphocytes, predominantly T-helper cells. (a) Macrophages engulf the antigen and secrete pro-inflammatory cytokines. They also present antigen derived peptides and lipids via MHC class II and CD 1 molecules to T cells, natural killer T cells (NKT cells), and natural killer cells (NK cells). (b) Th1 cells secrete IFN γ which activates dendritic cells. (c) Dendritic cells loaded with antigen migrate to the local lymph nodes where they present to naive CD4+ T cells. (d) Within the lymph node, the dendritic cells secrete IL-12 which stimulates these naive cells to differentiate into Th1 cells. These in turn secrete IL-2 to expand their population. (e) At the granuloma site, activated dendritic cells secrete copious amounts of TNF α which activates the endothelium, upregulating the number of adhesion molecules to allow

extravasation of Th1 cells and monocytes. (f) Th1 cells secrete IFN γ which stimulates monocytes to differentiate into macrophages. **(B)** Diagrammatic representation of the multistep pathogenesis of Crohn's disease. (1) Loss of integrity in the gut epithelium allows bacteria to leave the lumen and enter the tissue of the gut. (2) Defective autophagy. (3) Mutation of NOD2 leads to reduction in secretion of pro-inflammatory cytokines including TNF α . (4) Defect in Neutrophil function (monogenic diseases) or reduced chemotaxis (inherited or due to reduced TNF α secretion). This leads to persistence of bacterium in the tissues. (5) Mutational the IL23R on Th17 cells leads to increased survival of these cells and increased IL17 production. High levels of IL17 is associated with increased bowel inflammation in Crohn's. (6) Mutation of ATG16L (T300A) leads to a excessive of production of IL- β . (7) Mutation in NOD2 leads to reduced defensin production by intestinal Paneth cells.

are also evident in CGD patients (Rahman et al., 2009). Impaired macrophage function is also evident in CGD, with attenuated pro-inflammatory cytokine and increased IL-10 secretion following bacterial stimulation. The role this plays in the development of granulomatous inflammation is still unclear.

AUTOINFLAMMATORY STATES

Blau syndrome is another immune disease which features granuloma formation. This rare autosomal dominant disorder can be characterized by granulomatous polyarthritis, uveitis, macropapular skin lesions containing granulomas and cranial neuropathies. Crohn's-like disease occurs in 30% of patients (Geha et al., 2007). A missense mutation in *NOD2* drives this disease resulting in a gain of function and periodic episodes of fever and inflammation classic of this disorder (Fritz et al., 2006). This is a direct opposite of the loss of function seen in *NOD2* associated with Crohn's disease, although both conditions result in granuloma formation. Monocytes derived from patients with Blau syndrome after stimulation with macrophage colony-stimulating factor had a greater ability to form multinucleate giant cells compared to healthy controls (Yasui et al., 2010). Macrophages also displayed increased adherence and expression of inter-cellular adhesion molecule-1 (ICAM1), which could suggest an increase in ability for macrophage fusion and giant cell generation.

Blau syndrome granulomas are immunohistochemically distinct from those of Sarcoidosis or Crohn's. A thick halo of lymphocytes, particularly Th17 cells surrounds the macrophages (Rose et al., 2011). Another observation in Blau syndrome granulomas is the phagocytosis of lymphocytes which can be found with their cytoplasm intact within the multinucleate giant cells of the granuloma. The gain of function of *NOD2* and its role

in autophagy could explain this phenomenon. Granulomas in patients with Crohn's disease there is an absence of this halo of lymphocytes and an increase in neutrophils and sclerosis in the surrounding tissue (Janssen et al., 2012).

SUMMARY

Our understanding of the complex mechanisms that underlie granuloma formation and maintenance is growing, particularly the role of the innate immune system. Genetic studies have identified that many diseases of immune aberration and granuloma formation share common genetic backgrounds (Lees et al., 2011). Although, many of these diseases have multiple causal mutations associated with the disease process. Understanding the genetic overlap between these diseases is key to elucidating common pathways and mechanisms for the disease process in this specialized inflammatory response.

The key to finding new treatment strategies to combat granulomatous disorders lies with understanding the genetic and immunological background to immunodeficiency diseases that result in granuloma formation. Insight into the complex immune signaling pathways which drive these diseases will hopefully in turn highlight appropriate targets for novel therapeutic therapies. The fact that granuloma formation is associated with immunodeficiency states and also can be initiated in some diseases by immunomodulatory drugs highlights the need for caution in prescribing immunosuppressants to treat granulomatous diseases.

ACKNOWLEDGMENTS

HJP is funded by the small grants scheme from the Dental Faculty of the Royal College of Surgeons of England.

REFERENCES

- Ardeniz, O., and Cunningham-Rundles, C. (2009). Granulomatous disease in common variable immunodeficiency. *Clin. Immunol.* 133, 198–207.
- Barrett, J. C., Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., et al. (2008). Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat. Genet.* 40, 955–962.
- Berg, P. A. (2011). The role of the innate immune recognition system in the pathogenesis of primary biliary cirrhosis: a conceptual view. *Liver Int.* 31, 920–931.
- Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncan, A., et al. (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 447, 661–678.
- Bylund, J., MacDonald, K. L., Brown, K. L., Mydel, P., Collins, L. V., Hancock, R. E. W., et al. (2007). Enhanced inflammatory responses of chronic granulomatous disease leukocytes involve ROS-independent activation of NF-kappa B. *Eur. J. Immunol.* 37, 1087–1096.
- Chiam, L. Y. T., Verhagen, M. M. M., Haraldsson, A., Wulffraat, N., Driessen, G. J., Netea, M. G., et al. (2011). Cutaneous granulomas in ataxia telangiectasia and other primary immunodeficiencies: reflection of inappropriate immune regulation? *Dermatology* 223, 13–19.
- Clark, R. A., Malech, H. L., Gallin, J. I., Nunoi, H., Volpp, B. D., Pearson, D. W., et al. (1989). Genetic variants of chronic granulomatous disease – prevalence of deficiencies of 2 cytosolic components of the NADPH oxidase system. *N. Engl. J. Med.* 321, 647–652.
- Clay, H., Volkman, H. E., and Ramakrishnan, L. (2008). Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. *Immunity* 29, 283–294.
- Cooper, A. M., Dalton, D. K., Stewart, T. A., Griffin, J. P., Russell, D. G., and Orme, I. M. (1993). Disseminated tuberculosis in interferon-gamma gene-disrupted mice. *J. Exp. Med.* 178, 2243–2247.
- Davis, J. M., Clay, H., Lewis, J. L., Ghori, N., Herbomel, P., and Ramakrishnan, L. (2002). Real-time visualization of mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish embryos. *Immunity* 17, 693–702.
- Dinauer, M. C., Orkin, S. H., Brown, R., Jesaitis, A. J., and Parkos, C. A. (1987). The glycoprotein encoded by the X-linked chronic granulomatous-disease locus is a component of the neutrophil cytochrome-B complex. *Nature* 327, 717–720.
- Dong, H., Davis, R. J., and Flavell, R. A. (2002). MAP kinases in the immune response. *Annu. Rev. Immunol.* 20, 55–72.
- Dorhoi, A., Desel, C., Yermeev, V., Pradl, L., Brinkmann, V., Mollenkopf, H. J., et al. (2010). The adaptor molecule CARD9 is essential for tuberculosis control. *J. Exp. Med.* 207, 777–792.
- Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., et al. (2006). A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* 314, 1461–1463.
- Egen, J. G., Rothfuchs, A. G., Feng, C. G., Winter, N., Sher, A., and Germain, R. N. (2008). Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. *Immunity* 28, 271–284.
- Eyer, D., Petiau, P., Finck, S., Heid, E., Grosshans, E., and Lutz, P. (1998). Cutaneous granulomatous lesions in a patient with Griscelli syndrome. *Annales de Dermatologie et de Venerologie* 125, 727–728.
- Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., et al. (2010). Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat. Genet.* 42, 1118.

- Fritz, J. H., Ferrero, R. L., Philpott, D. J., and Girardin, S. E. (2006). Nod-like proteins in immunity, inflammation and disease. *Nat. Immunol.* 7, 1250–1257.
- Fujita, N., Itoh, T., Omori, H., Fukuda, M., Noda, T., and Yoshimori, T. (2008). The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy. *Mol. Biol. Cell* 19, 2092–2100.
- Gallerani, I., Innocenti, D. D., Coronella, G., Berti, S., Amato, L., Moretti, S., et al. (2004). Cutaneous sarcoid-like granulomas in a patient with X-linked hyper-IgM syndrome. *Pediatr. Dermatol.* 21, 39–43.
- Garchon, H. J., Luan, J. J., Eloy, L., Bedossa, P., and Bach, J. F. (1994). Genetic-analysis of immune dysfunction in non-obese diabetic (NOD) mice – mapping of a susceptibility locus close to the Bcl-2 gene correlates with increased resistance of NOD T-cells to apoptosis induction. *Eur. J. Immunol.* 24, 380–384.
- Gardet, A., and Xavier, R. J. (2012). Common alleles that influence autophagy and the risk for inflammatory bowel disease. *Curr. Opin. Immunol.* 24, 522–529.
- Geha, R. S., Notarangelo, L. D., Casanova, J. L., Chapel, H., Conley, M. E., Fischer, A., et al. (2007). Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. *J. Allergy Clin. Immunol.* 120, 776–794.
- Gerke, V., and Moss, S. E. (2002). Annexins: from structure to function. *Physiol. Rev.* 82, 331–371.
- Gregoriou, S., Trimis, G., Charissi, C., Kalogeromitros, D., Stefanaki, K., and Rigopoulos, D. (2008). Cutaneous granulomas with predominantly CD8(+) lymphocytic infiltrate in a child with severe combined immunodeficiency. *J. Cutan. Med. Surg.* 12, 246–248.
- Gupta, D., Agarwal, R., Aggarwal, A. N., and Jindal, S. K. (2012). Sarcoidosis and tuberculosis: the same disease with different manifestations or similar manifestations of different disorders. *Curr. Opin. Pulm. Med.* 18, 506–516.
- Hofmann, S., Franke, A., Fischer, A., Jacobs, G., Nothnagel, M., Gaede, K. I., et al. (2008). Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. *Nat. Genet.* 40, 1103–1106.
- Holland, S. M. (2010). Chronic granulomatous disease. *Clin. Rev. Allergy Immunol.* 38, 3–10.
- Hugot, J. P., Chamaillard, M., Zouali, H., Lesage, S., Cezard, J. P., Belaiche, J., et al. (2001). Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 411, 599–603.
- Ijspeert, H., Lankester, A. C., van den Berg, J. M., Wiegant, W., van Zelm, M. C., et al. (2011). Artemis splice defects cause atypical SCID and can be restored in vitro by an antisense oligonucleotide. *Genes Immun.* 12, 434–444.
- Inoue, T., Boyle, D. L., Corr, M., Hamaker, D., Davis, R. J., Flavell, R. A., et al. (2006). Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis. *Proc. Natl. Acad. Sci. U.S.A.* 103, 5484–5489.
- Intemann, C. D., Thye, T., Niemann, S., Browne, E. N. L., Chinbuah, M. A., Enimil, A., et al. (2009). Autophagy gene variant IRGM-261T contributes to protection from tuberculosis caused by *Mycobacterium tuberculosis* but not by *M. africanum* strains. *PLoS Pathog.* 5:e1000577. doi:10.1371/journal.ppat.1000577
- Ishii, E., Matui, T., Iida, M., Inamitu, T., and Ueda, K. (1987). Chediak-Higashi-syndrome with intestinal complication - report of a case. *J. Clin. Gastroenterol.* 9, 556–558.
- James, D. G. (2000). A clinicopathological classification of granulomatous disorders. *Postgrad. Med. J.* 76, 457–465.
- Janssen, C. E. I., Rose, C. D., De Hertogh, G., Martin, T. M., Meunier, B. B., Cimaz, R., et al. (2012). Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2-related disorders Blau syndrome and Crohn disease. *J. Allergy Clin. Immunol.* 129, 1076–1084.
- Kobayashi, S. D., Voyich, J. M., Braughton, K. R., Whitney, A. R., Nauseef, W. M., Malech, H. L., et al. (2004). Gene expression profiling provides insight into the pathophysiology of chronic granulomatous disease. *J. Immunol.* 172, 636–643.
- Kumar, D., Nath, L., Kamal, M. A., Varshney, A., Jain, A., Singh, S., et al. (2010). Genome-wide analysis of the host intracellular network that regulates survival of *Mycobacterium tuberculosis*. *Cell* 140, 731–743.
- Lawn, S. D., and Zumla, A. I. (2011). Tuberculosis. *Lancet* 378, 57–72.
- Lees, C. W., Barrett, J. C., Parkes, M., and Satsangi, J. (2011). New IBD genetics: common pathways with other diseases. *Gut* 60, 1739–1753.
- Levine, B., and Deretic, V. (2007). Unveiling the roles of autophagy in innate and adaptive immunity. *Nat. Rev. Immunol.* 7, 767–777.
- Levine, S., Smith, V. V., Malone, M., and Sebire, N. J. (2005). Histopathological features of chronic granulomatous disease (CGD) in childhood. *Histopathology* 47, 508–516.
- Lockhart, E., Green, A. M., and Flynn, J. L. (2006). IL-17 production is dominated by gamma delta T cells rather than CD4 T cells during *Mycobacterium tuberculosis* infection. *J. Immunol.* 177, 4662–4669.
- MacMicking, J. D., Taylor, G. A., and McKinney, J. D. (2003). Immune control of tuberculosis by IFN-gamma-inducible LRG-47. *Science* 302, 654–659.
- Marks, D. J. B., Harbord, M. W. N., MacAllister, R., Rahman, F. Z., Young, J., Al-Lazikani, B., et al. (2006). Defective acute inflammation in Crohn's disease: a clinical investigation. *Lancet* 367, 668–678.
- Marks, D. J. B., Miyagi, K., Rahman, F. Z., Novelli, M., Bloom, S. L., and Segal, A. W. (2009). Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. *Am. J. Gastroenterol.* 104, 117–124.
- Marks, D. J. B., and Segal, A. W. (2008). Innate immunity in inflammatory bowel disease: a disease hypothesis. *J. Pathol.* 214, 260–266.
- Martire, B., Rondelli, R., Soresina, A., Pignata, C., Brocchetto, T., Finocchi, A., et al. (2008). Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. *Clin. Immunol.* 126, 155–164.
- Massara, A., Cavazzini, L., La Corte, R., and Trotta, F. (2010). Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new “class effect” paradoxical phenomenon. Two case reports and literature review. *Semin. Arthritis Rheum.* 39, 313–319.
- Mathew, S., Bauer, K. L., Fiscoeder, A., Bhardwaj, N., and Oliver, S. J. (2008). The anergic state in sarcoidosis is associated with diminished dendritic cell function. *J. Immunol.* 181, 746–755.
- Miller, E. A., and Ernst, J. D. (2009). Anti-TNF α immunotherapy and tuberculosis reactivation: another mechanism revealed. *J. Clin. Invest.* 119, 1079–1082.
- Moins-Teisserenc, H. T., Gadola, S. D., Cella, M., Dunbar, P. R., Exley, A., Blake, N., et al. (1999). Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. *Lancet* 354, 1598–1603.
- Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., et al. (2001). A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature* 411, 603–606.
- Pearce, E. J., Kane, C. M., Sun, J., Taylor, J. J., Mckee, A. S., and Cervi, L. (2004). Th2 response polarization during infection with the helminth parasite *Schistosoma mansoni*. *Immunol. Rev.* 201, 117–126.
- Plantinga, T. S., Crisan, T. O., Oosting, M., van de Veerdonk, F. L., de Jong, D. J., Philpott, D. J., et al. (2011). Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. *Gut* 60, 1229–1235.
- Prescott, N. J., Fisher, S. A., Franke, A., Hampe, J., Onnie, C. M., Soars, D., et al. (2007). A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. *Gastroenterology* 132, 1665–1671.
- Prior, C., Knight, R. A., Herold, M., Ott, G., and Spiteri, M. A. (1996). Pulmonary sarcoidosis: patterns of cytokine release in vitro. *Eur. Respir. J.* 9, 47–53.
- Rahman, F. Z., Hayee, B., Chee, R., Segal, A. W., and Smith, A. M. (2009). Impaired macrophage function following bacterial stimulation in chronic granulomatous disease. *Immunology* 128, 253–259.
- Rahman, F. Z., Marks, D. J. B., Hayee, B. H., Smith, A. M., Bloom, S. L., and Segal, A. W. (2008). Phagocyte dysfunction and inflammatory bowel disease. *Inflamm. Bowel Dis.* 14, 1443–1452.
- Ramakrishnan, L. (2012). Revisiting the role of the granuloma in tuberculosis. *Nat. Rev. Immunol.* 12, 352–366.
- Rao, R. V., Poksay, K. S., Castro-Obregon, S., Schilling, B., Row, R. H., del Rio, G., et al. (2004). Molecular components of a cell death pathway activated by endoplasmic reticulum stress. *J. Biol. Chem.* 279, 177–187.
- Rastogi, R., Du, W. J., Ju, D. H., Pirockinaite, G., Liu, Y. S., Nunez, G., et al. (2011). Dysregulation of p38 and MKP-1 in response to NOD1/TLR4

- stimulation in sarcoid bronchoalveolar cells. *Am. J. Respir. Crit. Care Med.* 183, 500–510.
- Redford, P. S., Boonstra, A., Read, S., Pitt, J., Graham, C., Stavropoulos, E., et al. (2010). Enhanced protection to *Mycobacterium tuberculosis* infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. *Eur. J. Immunol.* 40, 2200–2210.
- Reich, J. M. (2003). Adverse long-term effect of corticosteroid therapy in recent-onset sarcoidosis. *Sarcoidosis Vasc. Diffuse Lung Dis.* 20, 227–234.
- Reich, J. M. (2012). On the nature of sarcoidosis. *Eur. J. Intern. Med.* 23, 105–109.
- Rieber, N., Hector, A., Kuijpers, T., Roos, D., and Hartl, D. (2012). Current concepts of hyperinflammation in chronic granulomatous disease. *Clin. Dev. Immunol.* 2012:252460. doi: 10.1155/2012/252460.
- Rose, C. D., Martin, T. M., and Wouters, C. H. (2011). Blau syndrome revisited. *Curr. Opin. Rheumatol.* 23, 411–418.
- Savill, J., and Fadok, V. (2000). Corpse clearance defines the meaning of cell death. *Nature* 407, 784–788.
- Schappi, M. G., Deffert, C., Fiette, L., Gavazzi, G., Herrmann, F. R., Belli, D. C., et al. (2008). Branched fungal beta-glucan causes hyperinflammation and necrosis in phagocyte NADPH oxidase-deficient mice. *J. Pathol.* 214, 434–444.
- Schinella, R. A., Greco, M. A., Cobert, B. L., Denmark, L. W., and Cox, R. P. (1980). Hermansky-Pudlak Syndrome with Granulomatous Colitis. *Ann. Intern. Med.* 92, 20–23.
- Schmid, D., Pypaert, M., and Munz, C. (2007). Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. *Immunity* 26, 79–92.
- Schuetz, C., Huck, K., Gudowius, S., Megahed, M., Feyen, O., Hubner, B., et al. (2008). An immunodeficiency disease with RAG mutations and granulomas. *N. Engl. J. Med.* 358, 2030–2038.
- Sebire, N. J., Haselden, S., Malone, M., Davies, E. G., and Ramsay, A. D. (2003). Isolated EBV lymphoproliferative disease in a child with Wiskott-Aldrich syndrome manifesting as cutaneous lymphomatoid granulomatosis and responsive to anti-CD20 immunotherapy. *J. Clin. Pathol.* 56, 555–557.
- Segal, A. W. (2005). How neutrophils kill microbes. *Annu. Rev. Immunol.* 23, 197–223.
- Segal, A. W., Webster, D., Jones, O. T. G., and Allison, A. C. (1978). Absence of a newly described cytochrome-B from neutrophils of patients with chronic granulomatous disease. *Lancet* 2, 446–449.
- Sewell, G. W., Marks, D. J. B., and Segal, A. W. (2009). The immunopathogenesis of Crohn's disease: a three-stage model. *Curr. Opin. Immunol.* 21, 506–513.
- Smith, A. M., Rahman, F. Z., Hayee, B., Graham, S. J., Marks, D. J. B., Sewell, G. W., et al. (2009). Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. *J. Exp. Med.* 206, 1883–1897.
- Sventoraityte, J., Zvirbliene, A., Franke, A., Kwiatkowski, R., Kiudelis, G., Kupcinskas, L., et al. (2010). NOD2, IL23R and ATG16L1 polymorphisms in Lithuanian patients with inflammatory bowel disease. *World J. Gastroenterol.* 16, 359–364.
- Taylor, R. C., Cullen, S. P., and Martin, S. J. (2008). Apoptosis: controlled demolition at the cellular level. *Nat. Rev. Mol. Cell Biol.* 9, 231–241.
- Torok, P., Glas, J., Endres, I., Tonenchi, L., Teshome, M. Y., Wetzke, M., et al. (2009). Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. *Am. J. Gastroenterol.* 104, 1723–1733.
- Travassos, L. H., Carneiro, L. A. M., Ramjeet, M., Hussey, S., Kim, Y. G., Magalhaes, J. G., et al. (2010). Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. *Nat. Immunol.* 11, 55–62.
- Van Limbergen, J., Russell, R. K., Nimmo, E. R., Ho, G. T., Arnott, I. D., Wilson, D. C., et al. (2007). Genetics of the innate immune response in inflammatory bowel disease. *Inflamm. Bowel Dis.* 13, 338–355.
- Volpp, B. D., Nauseef, W. M., and Clark, R. A. (1988). Two cytosolic neutrophil oxidase components absent in autosomal chronic granulomatous disease. *Science* 242, 1295–1297.
- Watt, F. E., James, O. F. W., and Jones, D. E. J. (2004). Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. *QJM* 97, 397–406.
- Wehkamp, J., Salzman, N. H., Porter, E., Nuding, S., Weichenthal, M., Petras, R. E., et al. (2005). Reduced Paneth cell alpha-defensins in ileal Crohn's disease. *Proc. Natl. Acad. Sci. U.S.A.* 102, 18129–18134.
- Wildenberg, M. E., Vos, A. C. W., Wolfkamp, S. C. S., Duijvestein, M., Verhaar, A. P., Te Velde, A. A., et al. (2012). Autophagy attenuates the adaptive immune response by destabilizing the immunologic synapse. *Gastroenterology* 142, 1493.
- Winkelstein, J. A., Marino, M. C., Johnston, R. B., Boyle, J., Curtin, J., Gallin, J. I., et al. (2000). Chronic granulomatous disease – report on a national registry of 368 patients. *Medicine (Baltimore)* 79, 155–169.
- Wolf, A. J., Linas, B., Trevejo-Nunez, G. J., Kincaid, E., Tamura, T., Takatsu, K., et al. (2007). *Mycobacterium tuberculosis* infects dendritic cells with high frequency and impairs their function in vivo. *J. Immunol.* 179, 2509–2519.
- Yasui, K., Yashiro, M., Tsuge, M., Manki, A., Takemoto, K., Yamamoto, M., et al. (2010). Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome its possible action and mechanism. *Arthritis Rheum.* 62, 250–257.
- Yoo, J., Wolgamot, G., Torgerson, T. R., and Sidbury, R. (2008). Cutaneous noncaseating granulomas associated with Nijmegen breakage syndrome. *Arch. Dermatol.* 144, 418–419.
- Zimmer, J., Andres, E., Donato, L., Hanau, D., Hentges, F., and de la Salle, H. (2005). Clinical and immunological aspects of HLA class I deficiency. *Qjm.* 98, 719–727.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 30 January 2013; accepted: 05 May 2013; published online: 24 May 2013.

Citation: Petersen HJ and Smith AM (2013) The role of the innate immune system in granulomatous disorders. *Front. Immunol.* 4:120. doi: 10.3389/fimmu.2013.00120

This article was submitted to *Frontiers in Inflammation*, a specialty of *Frontiers in Immunology*.

Copyright © 2013 Petersen and Smith. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.